Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Jul 18;19(8):1679–1687. doi: 10.1016/j.cgh.2020.07.026

Table 1.

Characteristics of HCC patients (n=655)

Variable No delay
(Diagnostic follow-
up ≤60 days) (%)
n=348
Diagnostic delay
>60 days (%)
n=307
P-value
Age at HCC diagnosis - - 0.84
 <50 years 10 (2.9) 6 (2.0)
 50-64 years 247 (71.0) 221 (72.0)
 65-79 years 70 (20.1) 64 (20.9)
 ≥80 years 21 (6.0) 16 (5.2)
Year of HCC diagnosis - - <0.001
 2006 67 (19.3) 16 (5.3)
 2007 53 (15.2) 49 (16.2)
 2008 80 (23.0) 63 (20.9)
 2009 80 (23.0) 86 (28.5)
 2010 59 (17.0) 68 (22.5)
 2011 9 (2.6) 20 (6.6)
Race/ethnicity - - 0.39
 White 203 (58.3) 174 (56.7)
 Black 94 (27.0) 78 (25.4)
 Hispanic 42 (12.1) 50 (16.3)
 Other 9 (2.6) 5 (1.6)
VA treatment facility location - - 0.79
 Central 57 (16.4) 50 (16.3)
 East 77 (22.1) 78 (25.4)
 South 134 (38.5) 114 (37.1)
 West 80 (23.0) 65 (21.2)
Hepatitis B (HBV) 20 (5.8) 13 (4.2) 0.40
Hepatitis C (HCV) 258 (74.1) 240 (78.2) 0.23
Diabetes mellitus 126 (36.2) 120 (39.1) 0.45
History of alcohol or drug abuse 183 (52.6) 174 (56.7) 0.29
Liver disease severity - - <0.001
 Child-Pugh class A 101 (29.8) 128 (44.6)
 Child-Pugh class B 178 (52.5) 132 (46.0)
 Child-Pugh class C 60 (17.7) 27 (9.4)
Barcelona staging - - <0.001
 A 37 (11.1) 71 (25.7)
 B 71 (21.3) 77 (27.9)
 C 138 (41.3) 91 (33.0)
 D 88 (26.4) 37 (13.4)
Lesion size - - <0.001
 <1 cm 20 (5.8) 99 (32.3)
 1-2 cm 183 (52.6) 182 (59.3)
 >2 cm 145 (41.7) 26 (15.2)
Deyo-Charlson Comorbidity Index - - 0.002
 0 60 (17.5) 29 (9.6)
 1 145 (42.3) 118 (38.9)
 ≥2 138 (40.2) 156 (51.5)